Skip to main content
. 2014 Mar 19;51(6):603–609. doi: 10.3109/02770903.2014.895012

Figure 3.

Figure 3.

Adjusted* mean changes from baseline in predose FEV1 by FAO category (LLN definition) in study I (mild-to-moderate asthma) and study II (moderate-to-severe asthma). Run-in treatment was placebo for study I and lower dose budesonide for study II (see “Methods” section for run-in and treatment details). *Data presented as least-squares mean unless otherwise noted. BUD/FM, budesonide/formoterol; FAO, fixed airflow obstruction; FEV1, forced expiratory volume in 1 s; LLN, lower limit of normal; PBO, placebo.